Mercury amalgam filling lawsuits represent a class of legal actions brought by patients and former patients who received dental amalgam fillings—metal restorations that contain approximately 50% mercury—and allegedly suffered health injuries as a result. For decades, dental amalgam has been the most commonly used filling material in dentistry, with millions of Americans receiving these fillings. However, growing scientific research and patient advocacy have challenged the safety profile that regulatory agencies maintain, leading to lawsuits seeking compensation for alleged mercury poisoning, neurological damage, and other chronic health conditions allegedly linked to exposure from these fillings. The litigation has intensified as international regulatory bodies reconsider amalgam’s status.
In January 2025, the European Union banned dental amalgam fillings for most uses, marking a significant shift in global regulation. Simultaneously, patient advocacy groups and medical organizations have renewed efforts to pressure the FDA into reconsidering its permissive stance. A 2025 petition submitted by the International Academy of Oral Medicine and Toxicology (IAOMT) and Dental Amalgam Mercury Solutions (DAMS INC) formally requested that the FDA ban mercury fillings or reclassify them from Class II to Class III devices. These developments have fueled new litigation and renewed interest from patients who believe they were harmed by amalgam exposure.
Table of Contents
- What Are the Health Claims in Mercury Amalgam Filling Lawsuits?
- The FDA’s Current Position and Classification History
- Recent Regulatory Developments Driving Renewed Litigation
- Identifying At-Risk Populations and the Vulnerability Factor
- The 2014 Legal Challenge and Ongoing Litigation History
- Mercury Content and Exposure Mechanisms
- The Future of Amalgam Regulation and Litigation Trends
- Conclusion
What Are the Health Claims in Mercury Amalgam Filling Lawsuits?
Plaintiffs in mercury amalgam lawsuits typically allege that mercury vapor released from their fillings caused systemic health injuries, including neurological damage, autoimmune disease, kidney dysfunction, and other chronic conditions. The mechanism of harm alleged in these cases is that dental amalgam fillings continuously release mercury vapor, especially during chewing, brushing, and eating hot foods. According to patient advocates and some practitioners, this chronic low-level exposure accumulates in the body over time, particularly affecting the nervous system and other sensitive organs. The allegations center on the fact that mercury is a known neurotoxin, which creates a fundamental contradiction in the FDA’s position that amalgam fillings are safe.
For example, a patient who received amalgam fillings in childhood and continued wearing them for 20 years might allege they developed multiple sclerosis, chronic fatigue syndrome, or neurological symptoms, and attribute these conditions to cumulative mercury exposure from the fillings. These cases often involve detailed medical testimony about the symptoms the patient experienced and expert analysis attempting to link those symptoms to mercury exposure levels. The challenge in these lawsuits is establishing causation—proving that the fillings, rather than other environmental or genetic factors, caused the plaintiff’s illness. Unlike asbestos litigation, where latency periods are well-established, mercury-amalgam causation remains scientifically contested.
The FDA’s Current Position and Classification History
The FDA maintains that dental amalgam fillings are safe for use in adults and children age 6 and older at current exposure levels and does not support a ban. This position has remained relatively consistent despite mounting international pressure and new scientific inquiries. In 2009, the FDA reclassified dental amalgam from Class I to Class II device status, which required special controls and enhanced labeling requirements. However, this reclassification did not restrict the use of amalgam or declare it unsafe—it simply subjected it to greater scrutiny and information requirements. The FDA has not gone further to classify it as a Class III device, which would impose even stricter controls and require pre-market approval for new formulations.
One limitation of the FDA’s position is that it is based on average exposure calculations and assumes average mercury vapor release rates. The agency acknowledges that certain populations face increased risk from mercury exposure, yet continues to permit widespread use of the material. The FDA explicitly does not recommend removing existing amalgam fillings in good condition unless medically necessary, citing the concern that removal itself can temporarily increase mercury vapor exposure. This creates a dilemma for patients: the fillings themselves are alleged to be harmful, yet removing them may temporarily worsen exposure. For a patient concerned about mercury toxicity, this guidance offers little reassurance or practical guidance.
Recent Regulatory Developments Driving Renewed Litigation
The European Union’s January 1, 2025 ban on dental amalgam represents a watershed moment in the global regulatory landscape. The EU ban permits amalgam use only when a dentist deems it “strictly necessary” based on specific patient needs—effectively restricting it to exceptional circumstances rather than routine use. This decision by one of the world’s largest economic blocs signals a major shift away from the material and has become a focal point in American litigation, with plaintiffs’ attorneys arguing that if the EU determined amalgam was unsafe enough to ban, the fda should follow suit. Simultaneously, the 2025 FDA petition filed by IAOMT and DAMS INC represents the most formal and comprehensive challenge to amalgam’s status in recent years.
The petition includes detailed scientific submissions requesting either an outright ban or reclassification to Class III status. The petition specifically emphasizes the at-risk populations that the FDA itself has identified—pregnant women, nursing mothers, children under 6, people with neurological diseases, those with kidney disease, and those with metal sensitivities. If the FDA were to reclassify amalgam to Class III, it would require pre-market approval for any amalgam formulation and could effectively end new amalgam placements in the United States. These regulatory developments have energized patient advocacy groups and created new impetus for litigation.
Identifying At-Risk Populations and the Vulnerability Factor
The FDA has formally identified specific populations at elevated risk from mercury exposure, even while maintaining that amalgam is safe for the general adult population. These at-risk groups include pregnant women, women who are nursing, children under 6 years old, people with diagnosed neurological diseases such as multiple sclerosis, Alzheimer’s disease, or Parkinson’s disease, individuals with impaired kidney function, and people with known metal sensitivities or allergies. This FDA acknowledgment of at-risk populations is significant in litigation because it concedes that mercury exposure poses varying levels of risk depending on individual circumstances.
Consider a concrete example: a woman who received amalgam fillings before becoming pregnant might later develop complications during pregnancy or give birth to a child with developmental issues. That woman could potentially argue that the FDA’s own guidance identifying pregnant women as at-risk should have prompted dentists to remove or avoid amalgam, but that standard of care was not uniformly followed. Similarly, a person diagnosed with early-stage Parkinson’s disease who had amalgam fillings for decades might argue that their neurological condition was worsened or triggered by chronic mercury exposure. The existence of the FDA’s at-risk population list creates a factual basis for arguing that dentists should have exercised heightened caution with identified vulnerable patients, and that failure to do so constituted negligence or breach of informed consent.
The 2014 Legal Challenge and Ongoing Litigation History
In March 2014, a lawsuit was filed in U.S. District Court for the District of Columbia seeking to compel the FDA to respond to a prior petition requesting that dental amalgam be banned. This litigation reflected decades of patient advocacy efforts to force regulatory action. However, the FDA ultimately denied the petition on January 27, 2015, maintaining its position that amalgam could remain on the market.
The denial of this petition and the court’s apparent acceptance of the FDA’s position created a temporary setback for mercury amalgam opponents, but litigation has continued on other fronts. The challenge in mercury amalgam litigation is that individual tort cases must succeed despite the FDA’s regulatory approval. Courts generally accord significant deference to FDA determinations about medical device safety, which creates a substantial barrier for plaintiffs alleging that an FDA-approved device harmed them. A plaintiff effectively must argue that the FDA’s safety determination was wrong, or that their particular exposure or individual susceptibility created injury despite the general safety conclusion. This is difficult but not impossible—numerous products have been successfully litigated despite FDA approval, particularly when new scientific evidence emerges or when specific subpopulations were not adequately considered in the original approval.
Mercury Content and Exposure Mechanisms
Dental amalgam fillings consist of approximately 50% mercury mixed with other metals including silver, tin, and copper. This mercury component exists in a bound metallic state, but research has documented that the fillings continuously release small amounts of mercury vapor, particularly during chewing, dental work, and exposure to heat. The release rate varies based on the age of the filling, the surface area exposed, the frequency and force of chewing, and individual factors affecting the oral environment.
A patient with multiple large amalgam fillings might experience measurably higher urinary mercury levels than someone without amalgam, or than they themselves had before receiving the fillings. While the FDA argues these exposure levels remain below levels shown to cause harm in scientific studies, opponents argue that chronic low-level exposure over decades accumulates to harmful levels, and that vulnerable populations face particular risk. The biochemical argument about mercury accumulation in nervous tissue is central to many plaintiffs’ claims, and expert witnesses in these cases often present evidence showing how mercury crosses the blood-brain barrier and accumulates in neurological tissue.
The Future of Amalgam Regulation and Litigation Trends
The convergence of the EU ban, the 2025 FDA petition, and heightened scientific scrutiny suggests that the regulatory landscape may be shifting. While the FDA has not yet indicated willingness to ban or severely restrict amalgam, the organization faces mounting pressure from international bodies, patient advocacy groups, and medical professionals. The next critical decision point will be how the FDA responds to the 2025 petition. If the agency denies it outright, litigation will likely continue unchanged.
However, if the FDA initiates a new regulatory review or signals openness to reclassification, it could trigger a wave of litigation as patients seek compensation for past exposure. Litigation strategies are also evolving as attorneys recognize that individual causation cases may be difficult to win given FDA approval. Class action approaches, failure-to-warn theories, and state law claims around informed consent and negligent placement may prove more successful than direct causation arguments. The EU’s regulatory decision, while not binding on American courts, provides persuasive authority that amalgam poses sufficient risks to warrant severe restrictions or elimination. As the scientific literature continues to accumulate and international consensus shifts against amalgam, the foundation for American litigation against dentists, amalgam manufacturers, and potentially regulatory agencies may strengthen.
Conclusion
Mercury amalgam filling lawsuits represent an emerging area of litigation in which patients allege that dental fillings containing approximately 50% mercury caused neurological, autoimmune, and other systemic injuries through chronic exposure to mercury vapor. While the FDA maintains that amalgam is safe for adults age 6 and older, the agency simultaneously acknowledges that specific populations—including pregnant women, children under 6, and people with neurological or kidney disease—face elevated risks. This contradiction between blanket approval and identification of at-risk populations creates the legal and factual foundation for ongoing litigation.
Recent regulatory developments, particularly the 2025 EU ban and the formal 2025 FDA petition for reclassification or outright prohibition, suggest the regulatory environment may be shifting. Patients who believe they were harmed by amalgam fillings, or who are concerned about ongoing exposure, should consult with a qualified attorney to evaluate their individual circumstances. Documentation of symptoms, medical records, and the date and extent of amalgam exposure will be critical in evaluating any potential claim. While these cases present significant legal challenges due to FDA approval and the ongoing scientific debate, the combination of mounting international restrictions and evolving litigation strategies may create new opportunities for affected patients to seek redress.